MétaCan
Menu
Back to cohort
Record W4391720973 · doi:10.1016/j.prdoa.2024.100239

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance

2024· article· en· W4391720973 on OpenAlexaff
Victor S.C. Fung, Jason Aldred, Martha P. Arroyo, Filip Bergquist, Agnita J.W. Boon, Manon Bouchard, Sarah Bray, Sara Dhanani, Maurizio Facheris, Nahome Fisseha, Eric Freire-Álvarez, Robert A. Hauser, Anna Jeong, Jia Jia, Pavnit Kukreja, Michael J. Soileau, Amy M. Spiegel, Saritha Talapala, Arjun Tarakad, Enrique Urrea‐Mendoza, Jorge Zamudio, Rajesh Pahwa

Bibliographic record

VenueClinical Parkinsonism & Related Disorders · 2024
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsUniversité LavalCégep de Lévis
FundersParkinsonfondenLEO PharmaSun PharmaGöteborgs UniversitetSahlgrenska UniversitetssjukhusetUniversity of WashingtonSage TherapeuticsNeurocrine BiosciencesAcorda TherapeuticsIpsenJazz PharmaceuticalsEVER Neuro PharmaMichael J. Fox Foundation for Parkinson's ResearchRevanceBoston Scientific CorporationH. Lundbeck A/SSunovionWashington State UniversityParkinson's FoundationAmneal PharmaceuticalsBiogenPfizerNorthwestern UniversityF. Hoffmann-La RocheMassachusetts General HospitalNeuraxpharmTeva Pharmaceutical IndustriesUS WorldMedsAllerganAstraZenecaEli Lilly and CompanySupernus PharmaceuticalsAbbVieSanofi
KeywordsMedicineAdverse effectDopaminergicIntensive care medicineDiseaseDeep brain stimulationParkinson's diseasePhysical medicine and rehabilitationInternal medicineDopamine

Abstract

fetched live from OpenAlex

Background: As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) provides steady dopaminergic stimulation that can reduce symptom fluctuation. Objective: Our aim is to review the initiation, optimization, and maintenance of LDp/CDp therapy, identify possible challenges, and share potential mitigations. Methods: Review available LDp/CDp clinical trial data for practical considerations regarding the management of patients during LDp/CDp therapy initiation, optimization, and maintenance based on investigator clinical trial experience. Results: LDp/CDp initiation, optimization, and maintenance can be done without hospitalization in the clinic setting. Continuous 24 h/day LDp/CDp infusion can offer more precise symptom control than oral medications, showing improvements in motor fluctuations during both daytime and nighttime hours. Challenges include infusion-site adverse events for which early detection and prompt management may be required, as well as systemic adverse events (eg, hallucinations) that may require adjustment of the infusion rate or other interventions. A learning curve should be anticipated with initiation of therapy, and expectation setting with patients and care partners is key to successful initiation and maintenance of therapy. Conclusion: Continuous subcutaneous infusion of LDp/CDp represents a promising therapeutic option for individuals with PD. Individualized dose optimization during both daytime and nighttime hours, coupled with patient education, and early recognition of certain adverse events (plus their appropriate management) are required for the success of this minimally invasive and highly efficacious therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: none
Teacher disagreement score0.003
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.324
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations36
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueClinical Parkinsonism & Related DisordersSame topicParkinson's Disease Mechanisms and TreatmentsFrench-language works237,207